Key Highlights
- Shares were up 7.24% at $13.62 in pre-market, from a $12.70 prior close.
- Revenue rose 18% to $149.0 million, and ARR reached $528.5 million, up 20%.
- Adjusted EBITDA was $53.6 million, a 36.0% margin, and GAAP Net Income was $26.7 million.
- The full-year adjusted EBITDA outlook was raised to $163 million to $166 million.
- Trailing twelve month free Cash Flow was $166.0 million, a 30.9% margin.
Cellebrite (NASDAQ:CLBT) shares were up 7.24% at $13.62 in pre-market on Thursday, from a prior close of $12.70. The digital investigative and intelligence software provider reported third quarter results with ARR, Revenue and adjusted EBITDA above its targets, according to its chief executive, and raised its full-year profit outlook.
Recurring Revenue and Profit Both Improve
Revenue was $149.0 million, up 18% from $126.0 million. Subscription revenue rose 20% to $134.9 million. Total ARR reached $528.5 million, up 20%, and the dollar-based net retention rate was 116%. GAAP gross Margin was 81.2%, down from 83.9%, while non-GAAP gross margin was 85.7%.
GAAP net income was $26.7 million, or $0.10 per diluted share, versus $20.2 million, or $0.08. Non-GAAP net income was $45.6 million, or $0.17 per diluted share. Adjusted EBITDA rose to $53.6 million from $37.7 million, and Operating Cash Flow was $56.6 million.
Outlook Adjusts for Cloud and AI Mix
Management raised its full-year 2026 adjusted EBITDA outlook to $163 million to $166 million and reaffirmed ARR of $550 million to $560 million, or 14% to 16% growth. It fine-tuned revenue targets to $553 million to $558 million, citing more ratable revenue from cloud and AI and less hardware revenue than in the third quarter. Fourth quarter revenue is expected at $145 million to $150 million, with adjusted EBITDA of $47 million to $50 million.
The company expects a free cash flow margin of about 30% for the full year. Third quarter free cash flow was $51.8 million.
Genesis, Redomicile Plans and Corellium Review
Cellebrite said its agentic AI solution Genesis gained traction in its first full quarter of availability and is now offered in Australia, the United Kingdom and the European Union. Management said it plans to use Genesis as the foundation for a next-generation investigations platform.
Cellebrite also plans to redomicile in the United States through a new parent company, subject to Shareholder and regulatory approvals, which it said could broaden its appeal through inclusion in key U.S. stock indices. Separately, its Corellium Acquisition remains under review by the Committee on Foreign Investment in the United States. The company said it has not received a final decision and cannot predict the outcome.
Call and Sector Backdrop
Management will host a conference call at 8:30 a.m. ET today. The gain comes as Nasdaq-100 futures were down about 0.9%, so pre-market moves may shift before the regular session opens.






Please wait processing your request...